Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Sean C. Beinart,P. Kolm,E. Veledar,Zefeng Zhang,E. Mahoney,O. Bouin,S. Gabriel,J. Jackson,Roland S. Chen,J. Caro,S. Steinhubl,E. Topol,W. Weintraub
DOI: https://doi.org/10.1016/J.JACC.2005.03.073
IF: 24
2005-09-06
Journal of the American College of Cardiology
Abstract:
What problem does this paper attempt to address?